search
Back to results

Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood

Primary Purpose

Rheumatoid Arthritis

Status
Completed
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
methotrexate
non-steroidal anti-inflammatory drug (NSAID)
leflunomide
methotrexate
non-steroidal anti-inflammatory drug (NSAID)
leflunomide
Acupuncture
Sponsored by
Chinese Academy of Sciences
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional basic science trial for Rheumatoid Arthritis focused on measuring Rheumatoid Arthritis, blood, gut intestinal microbiome

Eligibility Criteria

18 Years - 65 Years (Adult, Older Adult)FemaleAccepts Healthy Volunteers

Inclusion Criteria:

  • The patient should be diagnosed as the first or second stage of rheumatoid Arthritis (RA) and checked with X ray for additional diagnose.
  • diagnosed for RA according to ACR(1987)

  • the patient should be in the active stage of the disease, defined as：

    1. swollen joints >3
    2. tender joints > 5
    3. any one of the following： (c1.) morning stiffness lasting more than 45 minutes (c2.) Erythrocyte Sedimentation Rate (ESR) >= 28mm/h (c3.) C-reactive protein (CRP)>= 12mg/L
  • Should not be resistant to MTX nor leflunomide

  • Blood test should satisfy:

    1. Hemoglobin (Hb)>=85g/L
    2. White cell >=3.5 10+9/L
    3. Platelets >= 100 10+9/L
    4. Liver function: serum alanine aminotransaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBil) should be less than 1.5 times the upper limit of normal (ULN)
    5. Kidney function: Serum creatinine (Cr) level should be less than ULN.
    6. Pregnancy test should be negative
  • should be positive for anti-cyclic citrullinated protein antibodies (anti-CCP).
  • should agree to sign the informed consent

Exclusion Criteria:

  • Serious diseases affecting liver, kidney, heart and lung, or diseases related to hematologic，endocrine and nervous systems. .
  • Be treated by MTX or Leflunomide in the last 3 months.
  • Be treated with cortical hormone （could be intramuscular injection, intravenous injection or injection to articular cavity） in the last 4 weeks.
  • Be treated with biological agents, such as antagonist of TNF-alpha,IL-6, and CD20 mono antibody in the last 3 months.
  • Be treated by chronic medicine, such as immunosuppressive agent, Penicillamine, chloroquine and gold based Disease-modifying antirheumatic drugs (DMARDs) in the last 3 months.
  • Pregnant and breast-feeding woman
  • Having history of serious drug allergy
  • In the acute or chronic phase of infection (such as lung diseases)
  • Easy bleeding patients or patients with local skin infection (only for acupuncture)
  • The patients cannot accept acupuncture (only for acupuncture)
  • Be treated with acupuncture in the past 3 months（only for acupuncture）.
  • No pregnant and breast-feeding woman.
  • No history of serious drug allergy.

Sites / Locations

  • Shanghai GuangHua Hospital of integrated traditional and western medicine

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Active Comparator

Arm Label

Acupuncture

Control

Arm Description

Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)

Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)

Outcomes

Primary Outcome Measures

ACR20 Response Rate at 3 Weeks
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
ACR20 Response Rate at 3 Months
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)

Secondary Outcome Measures

ACR50 Response Rate at 3 Weeks
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
ACR50 Response Rate at 3 Months
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
ACR70 Response Rate at 3 Weeks
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
ACR70 Response Rate at 3 Months
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
DAS28 at Baseline
The DAS28 (disease activity score) considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst), plus levels of an acute phase reactant (either the level of erythrocyte sedimentation rate ESR (mm/h) or C-reactive protein CRP (mg/litre)). DAS28 values were calculated as follows: DAS28 (CRP) = 0.56*√(TJC28) +0.28*√(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28 (ESR) = 0.56*√(TJC28)+0.28*√(SJC28)+0.014*GH+0.70*ln(ESR), where TJC = tender joint count and SJC = swollen joint count. The scale does not have bounds. DAS28 total score < 2,6 means remission DAS28 total score ranged between 2.6-3.2 means inactive disease; DAS28 total score ranged between 3.3-5.1 means moderate disease activity; DAS28 total score >5.1 means very active disease
DAS28 at 3 Weeks
The DAS28 (disease activity score) considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst), plus levels of an acute phase reactant (either the level of erythrocyte sedimentation rate ESR (mm/h) or C-reactive protein CRP (mg/litre)). DAS28 values were calculated as follows: DAS28 (CRP) = 0.56*√(TJC28) +0.28*√(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28 (ESR) = 0.56*√(TJC28)+0.28*√(SJC28)+0.014*GH+0.70*ln(ESR), where TJC = tender joint count and SJC = swollen joint count. The scale does not have bounds. DAS28 total score < 2,6 means remission DAS28 total score ranged between 0-3.2 means inactive disease; DAS28 total score ranged between 3.3-5.1 means moderate disease activity; DAS28 total score >5.1 means very active disease
DAS28 at 3 Months
The DAS28 (disease activity score) considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst), plus levels of an acute phase reactant (either the level of erythrocyte sedimentation rate ESR (mm/h) or C-reactive protein CRP (mg/litre)). DAS28 values were calculated as follows: DAS28 (CRP) = 0.56*√(TJC28) +0.28*√(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28 (ESR) = 0.56*√(TJC28)+0.28*√(SJC28)+0.014*GH+0.70*ln(ESR), where TJC = tender joint count and SJC = swollen joint count. The scale does not have bounds. DAS28 total score < 2,6 means remission DAS28 total score ranged between 0-3.2 means inactive disease; DAS28 total score ranged between 3.3-5.1 means moderate disease activity; DAS28 total score >5.1 means very active disease

Full Information

First Posted
June 5, 2012
Last Updated
September 11, 2023
Sponsor
Chinese Academy of Sciences
Collaborators
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine
search

1. Study Identification

Unique Protocol Identification Number
NCT01619176
Brief Title
Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood
Official Title
Non Inferiority Trial for the Study of Acupuncture on Rheumatoid Arthritis
Study Type
Interventional

2. Study Status

Record Verification Date
September 2023
Overall Recruitment Status
Completed
Study Start Date
October 2012 (undefined)
Primary Completion Date
December 2014 (Actual)
Study Completion Date
December 2014 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Chinese Academy of Sciences
Collaborators
Shanghai Guanghua Hospital of Integrated Traditional Chinese and Western Medicine

4. Oversight

Data Monitoring Committee
No

5. Study Description

Brief Summary
Acupuncture is used and recommended by the WHO for the treatment of Rheumatoid Arthritis. The molecular bases of this recommendation are not known, the investigators want to compare with the usage of high-throughput molecular technologies the variations occurring in patients treated with acupuncture and conventional treatment with the ones treated with conventional treatment only. The investigators observe the variations in blood and in the gut microbiome.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Rheumatoid Arthritis
Keywords
Rheumatoid Arthritis, blood, gut intestinal microbiome

7. Study Design

Primary Purpose
Basic Science
Study Phase
Not Applicable
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
Non-Randomized
Enrollment
10 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Acupuncture
Arm Type
Experimental
Arm Description
Acupuncture plus conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
Arm Title
Control
Arm Type
Active Comparator
Arm Description
Conventional treatment (methotrexate+leflunomide+non-steroid anti-inflammatory drugs)
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Description
methotrexate: 7.5mg/week to 15mg/week for 3 months
Intervention Type
Drug
Intervention Name(s)
non-steroidal anti-inflammatory drug (NSAID)
Intervention Description
NSAID: 100mg twice a day for 3 months
Intervention Type
Drug
Intervention Name(s)
leflunomide
Intervention Description
leflunomide: 20mg/day for 3 months
Intervention Type
Drug
Intervention Name(s)
methotrexate
Intervention Description
methotrexate: 7.5mg/week to 15mg/week for 3 months
Intervention Type
Drug
Intervention Name(s)
non-steroidal anti-inflammatory drug (NSAID)
Intervention Description
NSAID: 100mg twice a day for 3 months
Intervention Type
Drug
Intervention Name(s)
leflunomide
Intervention Description
leflunomide: 20mg/day for 3 months
Intervention Type
Procedure
Intervention Name(s)
Acupuncture
Intervention Description
30 minutes acupuncture every other day for 3 months. Basic acupoints: Zusanli, st36; Taixi，KI3）; Shenxu, BL23 Additional acupoints due to personal condition: Waiguan，SJ5; Baxie，Ex-UE9;Yinlingquan，(SP9）; Quchi，LI11; Yanglingquan，GB34; Xuehai，SP10; Dazhu，BL11; Dazhui，DU14; Pixu，BL20.
Primary Outcome Measure Information:
Title
ACR20 Response Rate at 3 Weeks
Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
Time Frame
From baseline to 3 weeks
Title
ACR20 Response Rate at 3 Months
Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
Time Frame
From baseline to three months
Secondary Outcome Measure Information:
Title
ACR50 Response Rate at 3 Weeks
Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
Time Frame
From baseline to 3 weeks
Title
ACR50 Response Rate at 3 Months
Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
Time Frame
From baseline to three months
Title
ACR70 Response Rate at 3 Weeks
Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
Time Frame
From baseline to 3 weeks
Title
ACR70 Response Rate at 3 Months
Description
ACR criteria stands for: American College of Rheumatology Criteria. ACR criteria measures improvement in tender or swollen joint counts and improvement in three of the following five parameters: acute phase reactant (such as sedimentation rate) patient assessment physician assessment pain scale disability/functional questionnaire The number indicates the percentage of improvement in tender or swollen joint counts as well percentage improvement in three of the other five criteria (patient's assessment of pain, a physician's global assessment of disease, a patient's global assessment of disease, physical function as assessed by the Health Assessment Questionnaire-Disability Index (HAQ-DI), and the level of acute-phase reactant)
Time Frame
From baseline to three months
Title
DAS28 at Baseline
Description
The DAS28 (disease activity score) considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst), plus levels of an acute phase reactant (either the level of erythrocyte sedimentation rate ESR (mm/h) or C-reactive protein CRP (mg/litre)). DAS28 values were calculated as follows: DAS28 (CRP) = 0.56*√(TJC28) +0.28*√(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28 (ESR) = 0.56*√(TJC28)+0.28*√(SJC28)+0.014*GH+0.70*ln(ESR), where TJC = tender joint count and SJC = swollen joint count. The scale does not have bounds. DAS28 total score < 2,6 means remission DAS28 total score ranged between 2.6-3.2 means inactive disease; DAS28 total score ranged between 3.3-5.1 means moderate disease activity; DAS28 total score >5.1 means very active disease
Time Frame
At baseline
Title
DAS28 at 3 Weeks
Description
The DAS28 (disease activity score) considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst), plus levels of an acute phase reactant (either the level of erythrocyte sedimentation rate ESR (mm/h) or C-reactive protein CRP (mg/litre)). DAS28 values were calculated as follows: DAS28 (CRP) = 0.56*√(TJC28) +0.28*√(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28 (ESR) = 0.56*√(TJC28)+0.28*√(SJC28)+0.014*GH+0.70*ln(ESR), where TJC = tender joint count and SJC = swollen joint count. The scale does not have bounds. DAS28 total score < 2,6 means remission DAS28 total score ranged between 0-3.2 means inactive disease; DAS28 total score ranged between 3.3-5.1 means moderate disease activity; DAS28 total score >5.1 means very active disease
Time Frame
At 3 weeks
Title
DAS28 at 3 Months
Description
The DAS28 (disease activity score) considers 28 tender and swollen joint counts, general health (GH; patient assessment of disease activity using a 100 mm visual analogue scale (VAS) with 0 = best, 100 = worst), plus levels of an acute phase reactant (either the level of erythrocyte sedimentation rate ESR (mm/h) or C-reactive protein CRP (mg/litre)). DAS28 values were calculated as follows: DAS28 (CRP) = 0.56*√(TJC28) +0.28*√(SJC28)+0.014*GH+0.36*ln(CRP+1)+0.96; DAS28 (ESR) = 0.56*√(TJC28)+0.28*√(SJC28)+0.014*GH+0.70*ln(ESR), where TJC = tender joint count and SJC = swollen joint count. The scale does not have bounds. DAS28 total score < 2,6 means remission DAS28 total score ranged between 0-3.2 means inactive disease; DAS28 total score ranged between 3.3-5.1 means moderate disease activity; DAS28 total score >5.1 means very active disease
Time Frame
At 3 months

10. Eligibility

Sex
Female
Minimum Age & Unit of Time
18 Years
Maximum Age & Unit of Time
65 Years
Accepts Healthy Volunteers
Accepts Healthy Volunteers
Eligibility Criteria
Inclusion Criteria: The patient should be diagnosed as the first or second stage of rheumatoid Arthritis (RA) and checked with X ray for additional diagnose. diagnosed for RA according to ACR(1987) the patient should be in the active stage of the disease, defined as： swollen joints >3 tender joints > 5 any one of the following： (c1.) morning stiffness lasting more than 45 minutes (c2.) Erythrocyte Sedimentation Rate (ESR) >= 28mm/h (c3.) C-reactive protein (CRP)>= 12mg/L Should not be resistant to MTX nor leflunomide Blood test should satisfy: Hemoglobin (Hb)>=85g/L White cell >=3.5 10+9/L Platelets >= 100 10+9/L Liver function: serum alanine aminotransaminase (ALT), aspartate transaminase (AST) and total bilirubin (TBil) should be less than 1.5 times the upper limit of normal (ULN) Kidney function: Serum creatinine (Cr) level should be less than ULN. Pregnancy test should be negative should be positive for anti-cyclic citrullinated protein antibodies (anti-CCP). should agree to sign the informed consent Exclusion Criteria: Serious diseases affecting liver, kidney, heart and lung, or diseases related to hematologic，endocrine and nervous systems. . Be treated by MTX or Leflunomide in the last 3 months. Be treated with cortical hormone （could be intramuscular injection, intravenous injection or injection to articular cavity） in the last 4 weeks. Be treated with biological agents, such as antagonist of TNF-alpha,IL-6, and CD20 mono antibody in the last 3 months. Be treated by chronic medicine, such as immunosuppressive agent, Penicillamine, chloroquine and gold based Disease-modifying antirheumatic drugs (DMARDs) in the last 3 months. Pregnant and breast-feeding woman Having history of serious drug allergy In the acute or chronic phase of infection (such as lung diseases) Easy bleeding patients or patients with local skin infection (only for acupuncture) The patients cannot accept acupuncture (only for acupuncture) Be treated with acupuncture in the past 3 months（only for acupuncture）. No pregnant and breast-feeding woman. No history of serious drug allergy.
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Christine Nardini, PhD
Organizational Affiliation
Key laboratory of Computational Biology,Chines Academy of Sciences-Max Planck Institute-CAS MPG PICB
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Christine Nardini, PhD
Organizational Affiliation
Consiglio Nazionale delle Ricerche Istituto per le Applicazioni del Calcolo "Mauro Picone"
Official's Role
Study Chair
First Name & Middle Initial & Last Name & Degree
Yuanhua Liu
Organizational Affiliation
Shanghai Institute of Biochemistry and Cell Biology, CAS, Shanghai, PRC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Yongying Liang
Organizational Affiliation
Guanghua Hospital, Shanghai, PRC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Xiaoyuan Zhou
Organizational Affiliation
Group of Clinical Genomic Networks, Shanghai Institutes for Biological Sciences, CAS-MPG, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Jennifer E. Dent
Organizational Affiliation
Group of Clinical Genomic Networks, Shanghai Institutes for Biological Sciences, CAS-MPG, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ting Jiang
Organizational Affiliation
Department of Neurology, University of California, San Francisco, USA
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Ding Qin
Organizational Affiliation
Guanghua Hospital, Shanghai, PRC
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Youtao Lu
Organizational Affiliation
Group of Clinical Genomic Networks, Shanghai Institutes for Biological Sciences, CAS-MPG, China
Official's Role
Principal Investigator
First Name & Middle Initial & Last Name & Degree
Dongyi He
Organizational Affiliation
Guanghua Hospital, Shanghai, PRC
Official's Role
Study Director
Facility Information:
Facility Name
Shanghai GuangHua Hospital of integrated traditional and western medicine
City
Shanghai
State/Province
Shanghai
ZIP/Postal Code
200052
Country
China

12. IPD Sharing Statement

Links:
URL
https://link.springer.com/book/9783031348839
Description
Book chapter, planned release in November 2023
Available IPD and Supporting Information:
Available IPD/Information Type
Individual Participant Data Set
Available IPD/Information URL
http://www.ncbi.nlm.nih.gov/geo
Available IPD/Information Identifier
GSE59526

Learn more about this trial

Acupuncture Study on Rheumatoid Arthritis, Monitoring Microbiome and Blood

We'll reach out to this number within 24 hrs